

ASX Announcement

The Pew Charitable Trusts adds Recce's Lead Compound RECCE® 327 to List of Antibiotic Treatments in Clinical Development

Highlights:

- **RECCE® 327 included in The Pew Charitable Trusts' annual assessment of non-traditional antibiotic treatment in clinical development**
- **RECCE® 327 is the only synthetic polymer drug candidate for treating sepsis currently in development**
- **New “outside-the-box” drugs are critically needed, with conventional antibiotic pipeline extremely thin**

Sydney Australia, 15 March 2021: Recce Pharmaceuticals Ltd (**ASX:RCE**) (**FSE:R9Q**), is pleased to announce its lead compound RECCE® 327 (R327) has been added to The Pew Charitable Trusts' annual list of Non-traditional Products in Development to Combat Bacterial Infections identifying new antibiotic treatments in development worldwide.

The *Non-traditional Products in Development to Combat Bacterial Infections* register is a key part of the respected independent non-profit organisation's efforts to help health and medical researchers better understand bacterial infections and address antibiotic resistance. The Pew Charitable Trusts' stated mission is to serve the public interest by improving public policy, informing the public, and invigorating civic life.

Recce Pharmaceuticals Chief Executive Officer James Graham said, “We welcome inclusion of our lead compound in this important annual global record of efforts underway to address the urgent unmet medical need to develop new antibiotic treatments. May this bring light to those at risk or suffering from sepsis, an infection for which no specific treatments exist, at this time.”

The register of non-traditional treatments shows 36 candidates which are in clinical development as of March 2021. It includes new approaches ranging from well-known medical interventions, such as vaccines and immunotherapies, to new therapies which have never been approved for use in human medicine.



ASX: RCE

Head Office: Level 25, 88 Phillip Street, Aurora Place, SYDNEY NSW 2000 **T** +61 (02) 9256 2571

R&D Centre - Perth: Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

Washington Office: 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA

The list identifies each product and its manufacturer, type of approach, potential indications, target or mechanism of action, and stage in the clinical development process.




Image Source: The Pew Charitable Trusts 2021

This announcement has been approved for release by Recce Pharmaceuticals CEO.



Chief Executive Officer

James Graham
 Recce Pharmaceuticals Ltd
 +61 (02) 9256 2571
 james.graham@recce.com.au

Media and Investor Relations (AU)

Andrew Geddes
 CityPR
 +61 (02) 9267 4511
 ageddes@citypublicrelations.com.au

Media and Investor Relations (USA)

Meredith Sosulski, PhD
 LifeSci Communications
 +1 929 469 3851
 msosulski@lifescicomms.com

About Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of New Classes of Synthetic Anti-Infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens.

Recce's anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE[®] 327, RECCE[®] 435, and RECCE[®] 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.

Patented lead candidate RECCE[®] 327 has been developed for the treatment of blood infections and sepsis derived from *E. coli* and *S. aureus* bacteria – including their superbug forms. Recce's new antibiotic compound, RECCE[®] 435, has been formulated for oral use.

The FDA has awarded RECCE[®] 327 *Qualified Infectious Disease Product* designation under the *Generating Antibiotic Initiatives Now* (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. Further to this designation, RECCE[®] 327 has been included on The Pew Charitable Trusts *Global New Antibiotics in Development Pipeline* as the only synthetic polymer drug candidate for treating sepsis currently in development.

Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials. Recce's anti-infective pipeline seeks to exploit the unique capabilities of RECCE[®] technologies targeting synergistic, unmet medical needs.



Chief Executive Officer

James Graham
Recce Pharmaceuticals Ltd
+61 (02) 9256 2571
james.graham@recce.com.au

Media and Investor Relations (AU)

Andrew Geddes
CityPR
+61 (02) 9267 4511
ageddes@citypublicrelations.com.au

Media and Investor Relations (USA)

Meredith Sosulski, PhD
LifeSci Communications
+1 929 469 3851
msosulski@lifescicomms.com

recce.com.au
ACN 124 849 065